Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
- Author:
Jae Cheol LEE
1
;
Seung Hun JANG
;
Kye Young LEE
;
Young Chul KIM
Author Information
1. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Publication Type:Review
- Keywords:
EGFR tyrosine kinase inhibitor;
Non-small-cell lung carcinoma;
Drug resistance;
Neoplasms
- MeSH:
Carcinoma, Non-Small-Cell Lung;
Drug Resistance;
Epidermal Growth Factor;
Lung;
Population Characteristics;
Protein-Tyrosine Kinases;
Receptor, Epidermal Growth Factor
- From:Cancer Research and Treatment
2013;45(2):79-85
- CountryRepublic of Korea
- Language:English
-
Abstract:
Since the first description of non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutation as a distinct clinical entity, studies have proved EGFR tyrosine kinase inhibitors (TKIs) as a first choice of treatment. The median response duration of TKIs as a first-line treatment for EGFR mutant tumors ranges from 11 to 14 months. However, acquired resistance to EGFR-TKIs is inevitable due to various mechanisms, such as T790M, c-Met amplification, activation of alternative pathways (IGF-1, HGF, PI3CA, AXL), transformation to mesenchymal cell or small cell features, and tumor heterogeneity. Until development of a successful treatment strategy to overcome such acquired resistance, few options are currently available. Here we provide a summary of the therapeutic options after failure of first line EGFR-TKI treatment for NSCLC.
